DVAX vs. IRWD, LGND, GERN, MNKD, PRTA, INVA, OPK, LXRX, URGN, and PBYI
Should you be buying Dynavax Technologies stock or one of its competitors? The main competitors of Dynavax Technologies include Ironwood Pharmaceuticals (IRWD), Ligand Pharmaceuticals (LGND), Geron (GERN), MannKind (MNKD), Prothena (PRTA), Innoviva (INVA), OPKO Health (OPK), Lexicon Pharmaceuticals (LXRX), UroGen Pharma (URGN), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical preparations" industry.
Ironwood Pharmaceuticals (NASDAQ:IRWD) and Dynavax Technologies (NASDAQ:DVAX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation, community ranking and risk.
Ironwood Pharmaceuticals currently has a consensus target price of $19.80, indicating a potential upside of 141.76%. Dynavax Technologies has a consensus target price of $25.00, indicating a potential upside of 109.91%. Given Dynavax Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Ironwood Pharmaceuticals is more favorable than Dynavax Technologies.
Ironwood Pharmaceuticals received 38 more outperform votes than Dynavax Technologies when rated by MarketBeat users. However, 65.77% of users gave Dynavax Technologies an outperform vote while only 61.04% of users gave Ironwood Pharmaceuticals an outperform vote.
In the previous week, Ironwood Pharmaceuticals had 7 more articles in the media than Dynavax Technologies. MarketBeat recorded 9 mentions for Ironwood Pharmaceuticals and 2 mentions for Dynavax Technologies. Dynavax Technologies' average media sentiment score of 0.44 beat Ironwood Pharmaceuticals' score of -0.17 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media.
Ironwood Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Dynavax Technologies has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.
Dynavax Technologies has lower revenue, but higher earnings than Ironwood Pharmaceuticals. Dynavax Technologies is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Dynavax Technologies has a net margin of -2.75% compared to Dynavax Technologies' net margin of -226.37%. Ironwood Pharmaceuticals' return on equity of -1.08% beat Dynavax Technologies' return on equity.
97.0% of Dynavax Technologies shares are owned by institutional investors. 13.1% of Ironwood Pharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of Dynavax Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Ironwood Pharmaceuticals beats Dynavax Technologies on 10 of the 18 factors compared between the two stocks.
Get Dynavax Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dynavax Technologies Competitors List
Related Companies and Tools
